Curaleaf Announces New Branding For All Connecticut Dispensary Locations

Curaleaf Brand Coming to Recently Acquired Arrow Alternative Care and Grassroots Dispensaries in GrotonHartfordMilford and Stamford

MASSACHUSETTS: Curaleaf Holdings, Inc., a leading vertically integrated cannabis operator in the United States, announced new Curaleaf dispensary branding for all of the Company’s recently acquired Arrow Alternative Care and GR Companies, Inc. (“Grassroots”) dispensary locations in Connecticut. Curaleaf is the largest national retail dispensary brand in the U.S., and a premium mainstream cannabis brand available in 23 states as well as across a wide range of innovative products and form factors.

Joseph Lusardi, Chief Executive Officer of Curaleaf, said: “Building on our market leading position in Connecticut, we’re pleased to bring the Curaleaf branding to all four of our local medical cannabis dispensaries in the state. The rebranding of these locations directly aligns with our strategy of building strong, national brands that are renowned for high-quality products, backed by science, that deliver exceptional customer satisfaction.  With our Curaleaf brand in health and wellness, and our Select brand ranked as the #1 cannabis oil brand, we remain focused on providing our products directly to an expanding range of Connecticut patients. Overall, we are extremely proud to be active partners within these local communities and we look forward to building long-lasting relationships with them.”

Curaleaf began cultivating and processing medical cannabis in Connecticut in 2014. Today, Curaleaf is one of four licensed growers in Connecticut and operates a 60,000 square foot cultivation facility in Simsbury that provides high-quality cannabis products to over 9,000 patients statewide through its four dispensaries as well as wholesale channels.

In April of 2020, Curaleaf achieved vertical integration in Connecticut with the completion of its acquisition of Arrows’ dispensaries in Harford, Milford and Stamford, three of the largest Connecticut metro-areas. Under Curaleaf’s branding strategy, all three former Arrow dispensaries have been rebranded as Curaleaf dispensaries. Strategically placed in key metro areas, Arrow established itself as a market leader in Connecticut, operating three out of the 18 total dispensaries in the state. The Hartford dispensary opened in 2016, followed by Milford in 2017 and the Stamford store opening to customers in January of 2020. Additionally, in July of 2020, Curaleaf successfully completed the acquisition of Grassroots, including the Grassroots Herbology dispensary located in Groton, which has also been rebranded as a Curaleaf dispensary.

Curaleaf’s Connecticut dispensaries offers a broad range of flower, extracted oil and edible products manufactured to meet the highest product quality and regulatory compliance standards. Connecticut recently added as a qualifying medical condition Chronic Pain of at least six months duration associated with a specified underlying chronic condition refractory to other treatment intervention, which has the potential to significantly expand the size of the addressable market. In June of 2020, Curaleaf expanded its line of Select brand products into Connecticut with Select Elite Live cartridges available at local medical dispensaries across the state. Select, America’s #1 cannabis oil brand, can be found in 14 states including ArizonaCaliforniaColoradoConnecticutFloridaMarylandMichiganNevadaNew YorkOhioOklahomaOregonMassachusetts, and Maine. As a recognized industry leader, Select is committed to meeting high quality control standards and testing transparency as well as delivering a smooth, flavorful experience with all products formulated with strain-specific terpenes.

During the COVID-19 pandemic, Curaleaf dispensaries have been deemed an essential service in many states, including Connecticut. Curaleaf continues to serve patients and customers while implementing heightened safety and hygienic measures including increased cleaning protocols, social distancing, mobile pre-ordering, and curbside pickup for at-risk populations.

For additional information about Curaleaf’s Connecticut dispensaries please visit https://ct.curaleaf.com/

Curaleaf’s Select Elite Live Cartridges Reach $1M Sales In Florida Within 30 Days

MASSACHUSETTS  Curaleaf Holdings, a leading vertically integrated cannabis operator in the United States, today announced that its line of Select Elite Live cartridges has reached $1 million in sales since launching in the Florida medical market on August 6.Select Elite Live features high quality, high potency oil with a wide variety of strain-specific flavor and effects. Curaleaf will unveil additional Select product offerings to Florida’s medical patients later this year, including the best-selling high potency broad spectrum Select Elite cartridges. As a recognized industry leader, Select is committed to maintaining the highest quality control standards and testing transparency and delivering the best experience possible.

“We are thrilled to have received such a positive response to Elite Live from our Florida patients, and look forward to continuing to provide innovative new products for their cannabis needs,” said Joe Bayern, President of Curaleaf. “The immediate success of Elite Live in Florida speaks to the power of the Select brand, and we are confident about our continued growth in the state.”

Select, known as America’s #1 Cannabis Oil Brand, has been on a path of rapid expansion since it was acquired by Curaleaf in February 2020. Select products are now available in over 950 independent dispensaries across 12 states, including ArizonaCaliforniaColoradoConnecticutFloridaMarylandMichiganNevadaOklahomaOregonMassachusetts and Maine. The Select brand will continue to expand across the U.S. with its launch into Ohio’s medical market later this month.

Curaleaf has continued its retail expansion in Florida, recently announcing the opening of its Clearwater and South Tampa locations and plans to open a new Brandon area dispensary later this month.

Curaleaf Opens New Cannabis Dispensary In Clearwater, Florida

New Location Marks Curaleaf’s 29th Storefront in Florida and 89th Nationwide

FLORIDA: Curaleaf Holdings, a leading vertically integrated cannabis operator in the United States and one of the largest cannabis operators in Florida, announced today that it has opened a new dispensary in Clearwater, Florida, marking its 29th retail location in the state.Curaleaf Clearwater, located at 2082 Gulf to Bay Boulevard, will carry a wide range of Curaleaf and Select brand products. Select, known as America’s #1 cannabis oil brand now available in 12 states, launched earlier this month in Florida with Select Elite Live, the brand’s new enhanced live resin product, which combines high-quality THC oil and live resin high-terpene extract. The company also recently launched the first-to-market Curaleaf sublingual tablets. The Clearwater location is the first of three new medical dispensaries the company plans to open in the market this quarter.

“Curaleaf remains committed to the Florida market and its patients by providing high-quality medical cannabis products and new consumption formats that make cannabis accessible for all,” said Joe Bayern, President at Curaleaf. “We are thrilled to open Clearwater and support the health and wellness needs of more Floridians.”

Florida’s continued growth in patient registration makes it one of the nation’s fastest-growing medical cannabis markets in the country. Currently, there are over 394,000 medical patients enrolled in the Florida program – about 1.8% of the state’s population – with approximately 5,000 new patients joining each week.

In response to COVID-19, Curaleaf continues to implement new policies and procedures, including curbside services and contactless and cashless payment through approved credit and debit card services, to keep patients, customers and employees safe during this time. To see Curaleaf’s dispensary locations in Florida, please visit www.curaleaf.com/locations/#florida.

Curaleaf Completes The Acquisition Of Grassroots Creating The World’s Largest Cannabis Company

Market Leading U.S. Presence Across 23 States with Over 135 Dispensary Locations and Licenses

Mitchell Kahn, Grassroots Co-Founder and CEO, Appointed to the Curaleaf Board of Directors

MASSACHUSETTS:  Curaleaf Holdings, the largest vertically integrated cannabis operator in the United States, today announced that it closed its milestone acquisition of GR Companies the largest private vertically-integrated multi-state operator in the United States, on July 23, 2020.

With completion of the acquisition of Grassroots, Curaleaf is the world’s largest cannabis company by revenue and the most diversified vertically integrated cannabis company in the United States, the world’s largest cannabis market. The transaction expands Curaleaf’s presence from 18 to 23 states, with the combined company having affiliated operations spanning over 135 dispensary licenses, 88 operational dispensary locations, over 30 processing facilities and 22 cultivation sites with 1.6 million square feet of current cultivation capacity. Curaleaf’s expanded geographic dispensary presence now offers access to medical or adult use Cannabis to more than 192 million people, or roughly two-thirds of the United States population.

“The successful acquisition of Grassroots marks Curaleaf’s expansion into new vertically integrated markets in the Midwest, firmly establishing our U.S. market leadership position. This highly complementary combination brings together two companies with a shared vision for enhancing patients’ and customers’ lives with high-quality cannabis wellness and lifestyle products. I’d like to welcome all our new Grassroots colleagues, patients and customers to the Curaleaf family as we pursue our mission of improving lives by providing clarity around cannabis and confidence around consumption,” commented Joseph Lusardi, CEO of Curaleaf. “The integration of Grassroots is expected to be immediately accretive to our financial performance, with our unprecedented scale providing significant opportunities to leverage Curaleaf’s powerful consumer brands as well as new form factor innovations across our expanded national presence.”

Completion of the transaction strategically accelerates Curaleaf’s expansion into Illinois and Pennsylvania, which are among the largest and fastest-growing cannabis markets in the United States. Upon close, Curaleaf will hold a leading licensed cannabis presence in state markets including ArizonaConnecticutFloridaIllinoisPennsylvaniaMarylandMassachusettsMaineNevadaNew JerseyNew YorkNorth Dakota, and Vermont.

The cultivation and processing assets in Illinois have been transferred and the formal approval to transfer certain retail assets is expected imminently. Maryland operations previously affiliated with Grassroots may be transferred to Curaleaf after expiration of the statutory hold period, subject to regulatory approval and compliance with restrictions on ownership or control of multiple cultivation, processor and dispensary licenses in the State.

Mitchell Kahn, Co-Founder and CEO of Grassroots, commented, “Both Grassroots and Curaleaf are driven by a similar, positive culture and we are excited to join forces, adding scale and a combined strategic vision to create a dominant position in the industry. This opportunity would not have come to fruition without the strength of our highly skilled executive team, who have built an impressive portfolio at an unprecedented pace, with facilities in highly competitive markets. We look forward to integrating our talent and resources to build a great consumer product company – one that is dedicated to producing and delivering high-quality, safe and effective cannabis products to the customer.”

Curaleaf Announces New Board Member

Upon closing of the transaction, Curaleaf has appointed Mitchell Kahn, co-founder and CEO of Grassroots, to the company’s Board of Directors effective immediately. The appointment of Mr. Kahn expands the Curaleaf Board of Directors from five to six members.

“On behalf of the Curaleaf Board of Directors and management team, we are pleased to welcome Mitch to the Board. As a co-founder of Grassroots, he brings an impressive track record for success in building the largest private, vertically integrated U.S. multi-state cannabis operator. Combined with his deep experience across commercial real estate as well as the legal field, Mitch adds significant expertise and insight that will be vital as we extend our market leadership position and drive long-term shareholder value,” said Boris Jordan, Executive Chairman of Curaleaf.

Mr. Kahn co-founded Grassroots Cannabis in 2014 and brings more than 20 years of senior executive experience. He currently serves as Principal and CEO of Frontline Real Estate Partners, for which he is also a Founder, and previously served as President and CEO of Hilco Real Estate. Mr. Kahn is a CPA, as well as an attorney who has formerly practiced real estate law. He is a graduate of the University of Wisconsin, School of Business and Northwestern University, School of Law.

 

FDA Warning Letters And Test Results For Cannabidiol-Related Products

MJLegal

DISTRICT OF COLUMBIA: Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD).

As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products.

FDA WARNING LETTTERS

Curaleaf New Jersey Launches State’s First And Only Line Of Strain Specific Pure Cannabis Vape Concentrates

NEW JERSEY: Curaleaf New Jersey, a provider of state licensed cannabinoid-based products, today launched a new line of natural, terpene rich, strain specific, vaporable cannabis concentrates for patients of its Bellmawr dispensary. The first in New Jersey to manufacture products in this category, Curaleaf continues to set the industry standard by expanding its already-diverse medical cannabis product offerings. This new product line will help Curaleaf continue to provide quality care by offering a delivery form that addresses specific patient needs.

The newly-launched product is available initially in four varieties, Lavender, Strawberry Cough, Cookies and Canna-Tsu, all made with nothing but NJ Department of Health approved pharmaceutical-grade cannabis extract, strain specific cannabis and naturally derived terpenes. The product comes in the form of vaporizer cartridges and will soon be available in convenient disposable vape pens as well. Formulated by the Curaleaf team, these products are developed at the company’s cultivation and laboratory facility in Bellmawr using advanced extraction and processing techniques for the purest oil and most robust strain terpenes. The products are tested to ensure each cartridge has a standardized amount of THC and or CBD for a consistent patient experience.

“Receiving approval to launch these products is an important milestone in the progression of Curaleaf’s operations as well as in New Jersey’s medical cannabis program,” said George Schidlovsky, Curaleaf New Jersey’s president. “As the largest dispensary on the East Coast, serving hundreds of patients daily, Curaleaf has the resources and production capacity to reliably market and distribute new products that our patients depend on to live life well.”

“These concentrates, which surpass the state’s high standards of quality, provide an alternative method of administration for patients who may not be able to benefit from topical or oral forms of medical cannabis,” said Schidlovsky. “Vaporizing cannabis concentrate is considered a healthier alternative to smoking, and is a fast-acting form of administration. I look forward to seeing the positive effect it has on Curaleaf’s patients in New Jersey.”

Curaleaf Opens Medical Cannabis Dispensary In Oxford To Service Central Massachusetts

MASSACHUSETTS: Curaleaf, a provider of high-quality, reliable, and safe cannabinoid-based products, officially opened its second medical cannabis dispensary in Massachusetts. Now patients in central Massachusetts can more easily access needed medical care. This new location in Oxford joins the company’s successful Hanover dispensary that opened in fall of 2017.

Located at 425 Main Street, Curaleaf offers a range of innovative cannabis products, sold in a caring and compassionate environment. Curaleaf’s knowledgeable and experienced staff guide patients through the purchasing process, providing private, one-on-one consultation. The Oxford location will also continue to host monthly educational events open to the community to discuss topics such as the medical benefits of CBD and cooking with cannabis. Photos of the Oxford location can be found here.

“Many patients rely on medical cannabis as treatment for multiple conditions including epilepsy, cancer and PTSD,” said Patrik Johnson, Curaleaf President. “Before our Oxford location opened, many of these patients had to drive significant distances in order to purchase a needed medical aid. Curaleaf’s Oxford dispensary will make medical cannabis more accessible and provide patients with the most reliable and high-quality product on the market.”

The official opening was marked by a ribbon cutting joined by Selectman John Saad and Canna Care Docs.

“Safe access to Cannabis medicine is now available to residents of central Mass, and other Massachusetts medical Cannabis card holders,” said Kathleen McKinnon, Director of Operations for Canna Care Docs. “Canna Care Docs has educated and certified thousands of patients over the last 5 years. We have seen patients achieve relief and wellness with the opportunity to access medicine that has been lab tested and safely processed for consumption.”